IBSEN III (IBSEN III - Inflammatory Bowel Disease in South Eastern Norway - Institute of Clinical Medicine (uio.no)) is an observational, prospective population-based inception cohort study, including patients at all 15 hospitals in the South Eastern Health Region (HSØ). In total 2254 IBD patients and controls were included between 2017 and 2019. Today, the five-year follow-up is ongoing, and the study has become one of the world largest treatment naïve, and population-based IBD cohorts. Importantly the study includes a very large biobank with biological materials sampled at time of diagnosis and prospectively at one and five years.
Thirteen ongoing PhD projects and one postdoc at seven hospitals in HSØ is a major asset for the IBD research environment not only at OUH but in the whole region. The PhD projects span from clinical epidemiology, PROM-research, dietary epidemiology, and health economy to cutting edge translational projects on microbiomics, proteomics and transcriptomics.